Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616250 · ClinicalTrials.gov registry record · Phase 4
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 190
- Enrollment target
NCT02616250: Completed Phase 4 study, sponsored by Galderma R&D.
NCT02616250 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 190 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02616250, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 190 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
Primary Outcome
Percentage of patients defined as success as per scores of IGA; ie: clear (score=0) or almost clear (score=1)
Interventions
- DRUG Brimonidine 0.33% gel (Br)
- OTHER CD07805/47 (Br) placebo gel
- DRUG Ivermectin 1% cream (IVM)
- OTHER CD5024 (IVM) placebo cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 4 |
What the finished NCT02616250 record still lists
NCT02616250 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 4 interventions - of which Brimonidine 0.33% gel (Br) is the first listed.
NCT02616250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02616250 about?
NCT02616250 is a clinical study titled "MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.". The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
What is the current status of trial NCT02616250?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 190 participants. The study started on 2015-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02616250?
The interventions under investigation include: Brimonidine 0.33% gel (Br) (DRUG), CD07805/47 (Br) placebo gel (OTHER), Ivermectin 1% cream (IVM) (DRUG), CD5024 (IVM) placebo cream (OTHER).
Who is sponsoring clinical trial NCT02616250?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02616250's enrollment target sits among peer trials
190 453rd of 2000 higher than 1,545 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia